The effects of desferrioxamine on cisplatin-induced lipid peroxidation and the activities of antioxidant enzymes in rat kidneys

Human and Experimental Toxicology

Volumn 23, Issue 1, 2004, Pages 29-34

  Kadikoylu, Gurhan ^a   Bolaman, Z ^a   Demir, S ^b   Balkaya, M ^a   Akalin, N ^b   Enli, Y ^b  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

^b PAMUKKALE UNIVERSITY   (Turkey)

Author keywords

Antioxidant enzymes; Cisplatin; Desferrioxamine; Lipid peroxidation; Vitamin C; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CATALASE; CISPLATIN; DEFEROXAMINE; GLUTATHIONE REDUCTASE; HYDROGEN PEROXIDE; MALONALDEHYDE; SODIUM CHLORIDE; SUPEROXIDE DISMUTASE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CERVICAL SPINE DISLOCATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; INTERMETHOD COMPARISON; KIDNEY; LIPID PEROXIDATION; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SPECTROPHOTOMETRY; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; ASCORBIC ACID; CATALASE; CISPLATIN; DEFEROXAMINE; FEMALE; GLUTATHIONE REDUCTASE; IRON CHELATING AGENTS; KIDNEY; LIPID PEROXIDATION; MALE; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE; VITAMIN E;

RATTUS NORVEGICUS;

EID: 1342284961     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/0960327104ht413oa     Document Type: Article

References (38)

1. Weiss RB. Cancer: principles and practice of oncology. Philadelphia, PA: Lippincott Williams & Wilkins Press, 2001.
2. Piccart MJ, Lamb H, Vermorken JB. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol 2001; 12: 1195-203.
3. Daugaard G, Abildgaard U, Holstein-Rathlou NH, Bruunshuus I, Bucher D, Leyscsac PP. Renal tubular function in patients treated with high dose cisplatin. Clin Pharmacol Ther 1988; 44: 164-72.
4. Sadzuka Y, Shoji T, Takino Y. Mechanism of the increase in lipid peroxide induced by cisplatin in the kidneys of rats. Toxicol Lett 1992; 62: 293-300.
5. Antunes GLM, Darin JD, Bianchi MD. Protective effects of vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependent study. Pharmacol Res 2000; 41: 405-11.
6. Hannemann J, Duwe J, Baumann K. Iron and ascorbic acid-induced lipid peroxidation in renal microsomes isolated from rats treated with platinum compounds. Cancer Chemother Pharmacol 1991; 28: 427-33.
7. Emerit J, Beaumont C, Trivin F. Iron metabolism, free radicals and oxidative injury. Biomed Pharmacother 2001; 55: 333-39.
8. Vermeulen NPE, Baldew GS. The role of lipid peroxidation in the nephrotoxicity of cisplatin. Biochem Pharmacol 1992; 44: 1193-99.
9. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101-12.
10. Bolaman Z, Koseoglu MH, Demir S, Atalay H, Akalin N, Hatip I, Aslan D. Effect of amifostine on lipid peroxidation caused by cisplatin in rat kidney. J Chemother 2001; 13: 337-39.
11. Bolaman Z, Koseoglu MH, Demir S, Kadikoylu G, Barutca S, Atalay H, Aslan D. Effect of α-tocopherol on lipid peroxidation caused by cisplatin in rat kidney. Turk J Haematol 2003; 20: 35-38.
12. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89: 739-61.
13. Watanabe H, Kanno H. Experimental studies of the protective effect of deferoxamine mesilate on cisplatin induced toxicity. Nippon Jibiinkoka Jake Kaiho 1998; 101: 967-78.
14. Liu H, Baliga R. Effect of iron chelator, hydroxyl radical scavenger and cytochrome P450 inhibitors on the cytotoxicity of cisplatin to tumor cells. Anticancer Res 2000; 20: 4547-50.
15. Inselmann G, Blohmer A, Kottny W, Nellessen U, Hanel H, Heidemann HT. Modification of cisplatin-induced renal p-aminohippurate uptake alteration and lipid peroxidation by thiols, Ginkgo biloba extract, deferoxamine and torbafylline. Nephron 1995; 70: 425-29.
16. Suzer T, Coskun E, Demir S, Tahta K. Lipid peroxidation and glutathione levels after cortical injection of ferric chloride in rats: effect of trimetazidine and deferoxamine. Res Exp Med 2000; 199: 223-29.
17. Gerard-Monnier D, Erdelmeier I, Regnard K, Moze-Henry N, Yadan JC, Chaudiere J. Reactions of 1-methyl-2-phenilodine with malondialdehyde and 4-hydroxyalkenals. Analytical applications to a colorimetric assay of lipid peroxidation. Chem Res Toxicol 1998; 11: 1176-83.
18. Nebot C, Moutet M, Huet P, Xu JZ, Yadan JC, Chaudiere J. Spectrophotometric assay of superoxide dismutase activity based on the activated autoxidation of a tetracyclic catechol. Anal Biochem 1993; 214: 442-51.
19. Worthington DJ, Rosemeyer MA. Glutathione reductase from human erythrocytes. Catalytic properties and aggregation. Eur J Biochem 1976; 67: 231-38.
20. Fossati P, Perencipe L, Berti G. Use of 3,5-dichloro-2-hydroxybenzenesulfonic acid/4-aminophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine. Clin Chem 1980; 26: 227-31.
21. Gay C, Gebicki JM. A critical evaluation of the effect of sorbitol on the ferric-xylenol orange hydroperoxide assay. Anal Biochem 2000; 284: 217-20.
22. Capizzi RL. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspect. Semin Oncol 1999; 26(suppl 7): 72-81.
23. Shenberg C, Izak-Biran T, Mantel M, Rachmiel B, Weinnger J, Chaitchik S. Effect of selenite on the toxicity of cis-DDP in mice: estimation of trace elements. J Trace Elem Electrolytes Health Dis 1989; 3: 71-75.
24. Winterbourn CC, Vile GF, Monteiro HP. Ferritin, lipid peroxidation and redox-cycling xenobiotics. Free Radic Res Commun 1991; 12-13: 107-114.
25. Gutteridge JMC, Rowley DA, Griffiths E, Halliwell B. Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. Clin Sci 1985; 68: 463-67.
26. Kameyama Y, Gemba M. The iron chelator deferoxamine prevents cisplatin-induced lipid peroxidation in rat kidney cortical slices. Jpn J Pharmacol 1991; 57: 259-62.
27. Dehne N, Lautermann J, Petrat F, Rauen U, de Groot H. Cisplatin ototoxicity: involvement of iron and enhanced formation of superoxide anion radicals. Toxicol Appl Pharmacol 2001; 174: 27-34.
28. al-Harbi MM, Osman AM, al-Gharably NM, al-Bekairi AM, al-Shabanah OA, Sabah DM, Raza M. Effect of desferrioxamine on cisplatin-induced nephrotoxicity in normal rats. Chemotherapy 1995; 41: 448-54.
29. JF Head, Wang F, Elliott RL. Antineoplastic drugs that interfere with iron metabolism in cancer cells. Adv Enzyme Regul 1997; 37: 147-69.
30. Voest EE, Neijt JP, Keunen JE, Dekker AW, van Asbeck BS, Nortier JW, Ros FE, Marx JJ. Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity. Cancer Chemother Pharmacol 1993; 31: 357-62.
31. Babu E, Gopalakrishnan VK, Sriganth INP, Gopalakrishnan R, Sakthisekaran D. Cisplatin induced nephrotoxicity and the modulating effect of glutathione ester. Mol Cell Biochem 1995; 144: 7-11.
32. Sadzuka Y, Shoji T, Takino Y. Effect of cisplatin on the activities of enzymes which protect against lipid peroxidation. Biochem Pharmacol 1992; 43: 1872-75.
33. Sharma RP. Interactions of cis-platinum with cellular zinc and copper in rat liver and kidney tissues. Pharmacol Res Commun 1975; 17: 197-206.
34. Durak I, Ozbek H, Karaayvaz M, Ozturk HS. Cisplatin induces acute renal failure by impairing antioxidant system in guinea pigs: effects of antioxidant supplementation on the cisplatin nephrotoxicity. Drug Chem Toxicol 2002; 25: 1-8.
35. Keese MA, Saffrich R, Dandekar T, Becker T, Schirmer RH. Microinjected glutathione reductase crystals as indicators of the redox status in living cells. FEBS Lett 1999; 447: 135-38.
36. el Daly ES. Protective effect of cysteine and vitamin E, Crocus sativus and Nigella sativa extracts on cisplatin-induced toxicity in rats. J Pharm Belg 1998; 53: 87-93.
37. Kirkman HN, Rolfo M, Ferraris AM, Gaetani GF. Mechanisms of protection of catalase by NADPH. Kinetics and stoichiometry. J Biol Chem 1999; 274: 13908-14.
38. Shi XG, Sun XL, Gannett PM, Dalal NS. Deferoxamine inhibition of Cr (V)-mediated radical generation and deoxyguanine hydroxylation: ESR and HPLC evidence. Arch Biochem Biophys 1992; 293: 281-86.